Press Release Sep 15 2025
Filed with NSE · · 5 pages · English
Summary by 6ix AI
The first product is a generic treatment for canine urinary incontinence, providing cost-effective relief for aging dogs. The second product is an affordable formulation of Furosemide tablets, aimed at managing heart conditions in dogs and cats. Both products are designed to enhance accessibility and affordability of veterinary care for pet owners and professionals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 05 2025
- Press Release Sep 04 2025
- Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market
- Press Release Sep 02 2025
- Press Release Aug 29 2025
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Sep 21 2025
- Press Release Sep 23 2025
- Press Release Oct 01 2025
- Press Release Oct 06 2025
- Press Release Oct 24 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences